CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Stock Balance Sheet
NASDAQ:CYCCP - Nasdaq - US23254L2079 - Currency: USD
| MRQ (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 3.45M | 3.14M | 3.38M | 18.35M | 36.56M | |||
| Receivables | 70.00K | 0.00 | 2.93M | 4.66M | 3.73M | |||
| Other Current Assets | 194.00K | 537.00K | 1.13M | 1.41M | 660.00K | |||
| Total Current Assets | 3.71M | 3.67M | 7.44M | 24.41M | 40.94M | |||
| Non-Current Assets | ||||||||
| PPE Net | 20.00K | 8.00K | 102.00K | 170.00K | 90.00K | |||
| Other Non-Current Assets | N/A | 412.00K | 1.26M | 2.92M | 1.55M | |||
| Total Non-Current Assets | 20.00K | 420.00K | 1.36M | 3.09M | 1.65M | |||
| TOTAL ASSETS | 3.73M | 4.09M | 8.80M | 27.50M | 42.59M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 532.00K | 1.39M | 4.24M | 3.94M | 2.54M | |||
| Accounts Payable | 114.00K | 4.60M | 3.54M | 2.56M | 2.12M | |||
| Other Current Liabilities | 17.00K | 283.00K | 380.00K | 890.00K | 630.00K | |||
| Total Current Liabilities | 663.00K | 6.27M | 8.16M | 7.39M | 5.29M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 9.00K | 0.00 | 37.00K | 110.00K | 30.00K | |||
| Total Non-Current Liabilities | 9.00K | 0.00 | 37.00K | 110.00K | 30.00K | |||
| TOTAL LIABILITIES | 672.00K | 6.27M | 8.20M | 7.50M | 5.32M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -440.46M | -439.49M | -428.28M | -406.16M | -384.96M | |||
| Additional Paid In Capital | 443.32M | 438.20M | 429.80M | 422.97M | 422.96M | |||
| Common Shares | 205.00K | 9.00K | 1.00K | 4.50M | 10.00K | |||
| Other Shareholders' Equity | N/A | -891.00K | -908.00K | -1.32M | -750.00K | |||
| Shares Outstanding | 12.96M | 553.70K | 66.20K | 12.54M | 9.99M | |||
| Tangible Book Value per Share | 0.24 | -3.93 | 9.17 | 1.59 | 3.73 | |||
| Total Shareholders' Equity | 3.06M | -2.17M | 607.00K | 20.00M | 37.26M | |||
| TOTAL LIABILITIES AND EQUITY | 3.73M | 4.09M | 8.80M | 27.50M | 42.59M | |||
| Statistics | ||||||||
| Current Ratio | 5.60 | 0.59 | 0.91 | 3.30 | 7.74 | |||
| Return On Assets (ROA) | -223.54% | -273.86% | -258.44% | -77.82% | -44.82% | |||
| Return On Equity (ROE) | -272.60% | N/A | -3748.93% | -107.00% | -51.23% | |||
All data in USD , ROIC based on taxRate of 0.21